These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 19821717)

  • 1. Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial.
    Liu JZ; Chen SG; Zhang B; Wang CB; Zhao XW; Li GY; Wang LX
    J Altern Complement Med; 2009 Oct; 15(10):1127-30. PubMed ID: 19821717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: a pilot randomized and placebo-controlled clinical trial.
    Li GY; Yu XM; Zhang HW; Zhang B; Wang CB; Xin YC; Yang CZ; Zhou RX; Wang LX
    Complement Ther Med; 2009 Jan; 17(1):51-5. PubMed ID: 19114229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegillarca granosa extract Haishengsu (HSS) suppresses expression of mdr1, BCR/ABL and sorcin in drug-resistant K562/ADM tumors in mice.
    Li GY; Liu JZ; Zhang B; Yang M; Chen SG; Hou M; Wang LX
    Adv Med Sci; 2013; 58(1):112-7. PubMed ID: 23729583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Hong SK; Kwak C; Lee SE
    Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
    O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
    Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
    Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
    Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marine drug Haishengsu increases chemosensitivity to conventional chemotherapy and improves quality of life in patients with acute leukemia.
    Li GY; Zhang L; Liu JZ; Chen SG; Xiao TW; Liu GZ; Wang JX; Wang LX; Hou M
    Biomed Pharmacother; 2016 Jul; 81():160-165. PubMed ID: 27261590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysis.
    Roigas J; Deger S; Taymoorian K; Wille AH; Johannsen M; Türk I; Schnorr D; Loening SA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):157-63. PubMed ID: 12804041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
    Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
    Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.
    Ellerhorst JA; Sella A; Amato RJ; Tu SM; Millikan RE; Finn LD; Banks M; Logothetis CJ
    Cancer; 1997 Dec; 80(11):2128-32. PubMed ID: 9392335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanism Inducing the HL-60 Cell Differentiation by Haishengsu Tegillarca Granosa Extract via Targeting ULK1 Protein].
    Zhong M; Su QH; Xu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):141-145. PubMed ID: 32027267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.
    Marx G; Taylor J; Goldstein D
    Intern Med J; 2005 Jan; 35(1):34-8. PubMed ID: 15667466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Rexer H
    Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapeutic treatment for metastatic renal carcinoma].
    Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
    Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer].
    Vozianov AF; Zak KP; Zubko VI; Romanenko AM; Klimenko IA; Babich VM; Kushneruk IuI; Shcherbak AIu; Bazalitskaia SV; Gruzov MA
    Lik Sprava; 2002; (7):41-7. PubMed ID: 12587303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC).
    Passalacqua R; Caminiti C; Buti S; Porta C; Camisa R; Braglia L; Tomasello G; Vaglio A; Labianca R; Rondini E; Sabbatini R; Nastasi G; Artioli F; Prati A; Potenzoni M; Pezzuolo D; Oliva E; Alberici F; Buzio C;
    J Immunother; 2014; 37(9):440-7. PubMed ID: 25304727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
    Atzpodien J; Kirchner H; Illiger HJ; Metzner B; Ukena D; Schott H; Funke PJ; Gramatzki M; Jürgenson S; Wandert T; Patzelt T; Reitz M
    Br J Cancer; 2001 Oct; 85(8):1130-6. PubMed ID: 11710825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.